Otolaryngology‐Head and Neck Surgery

ogy (ACAAI); and the American Rhinologic Society (ARS), convened a group of 30 physicians from a wide range of disciplines: allergy-immunology, otolaryngology, infectious disease, and radiology. Over 2 days, this panel worked together to develop definitions of rhinosinusitis for clinical research and to suggest clinical trial designs for studies that would allow for more appropriate use of pharmacologic, immunologic, and surgical interventions. Using an anonymous electronic audience response system, the committee was able to Institutes of Health; and is employed by Georgetown University. F. M. Baroodyis on the Speaker's Bureaufor Merck& Co, Inc, and GlaxoSmith-Kline.